Developmental toxicity study in rats treated with the anticonvulsant, ralitoline

Area of Science:

• Toxicology
• Developmental Biology
• Pharmacology

Background:

• Anticonvulsant medications are crucial for managing epilepsy, but their safety during pregnancy requires thorough investigation.
• Ralilotine is an anticonvulsant compound whose developmental toxicity has not been fully elucidated.
• Understanding the potential risks of ralitoline exposure during gestation is essential for maternal and fetal health.

Purpose of the Study:

• To evaluate the developmental toxicity of the anticonvulsant ralitoline in Sprague-Dawley rats.
• To determine dose-related effects on maternal health and fetal development following oral administration during gestation.
• To identify specific malformations and variations induced by ralitoline exposure.

Main Methods:

• Sprague-Dawley rats were administered oral doses of ralitoline (0, 15, 60, 120, 180, 240 mg/kg) from gestation days 6-15.
• Control groups included untreated and pair-fed to the high dose.
• Maternal and fetal parameters were assessed on gestation day 21, with detailed examination of fetuses for malformations and variations.

Main Results:

• Maternal mortality occurred at 180 and 240 mg/kg, with dose-dependent decreases in body weight, food, and water consumption from 60 mg/kg.
• Central nervous system signs were observed at 60 mg/kg and above.
• Significant increases in postimplantation loss, fetal malformations (especially cardiovascular), and skeletal variations were observed at 120 mg/kg and above.

Conclusions:

• Ralilotine exhibits significant developmental toxicity in Sprague-Dawley rats, including maternal toxicity and teratogenicity.
• Dose-dependent adverse effects on fetal development, particularly cardiovascular malformations, were evident.
• These findings suggest a potential risk associated with ralitoline exposure during pregnancy.